Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac<sup>®</sup> and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study

Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac<sup>®</sup> and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study

Background: Vaccines that prevent SARS-CoV-2 infection are considered the most promising approach to modulating the pandemic. There is scarce evidence on the efficacy and safety of different vaccine prime-boost combinations in MHD patients since most clinical trials have used homologous mRNA vaccine...

Full description

Bibliographic Details
Main Authors: Phoom Narongkiatikhun, Kajohnsak Noppakun, Romanee Chaiwarith, Poramed Winichakoon, Surachet Vongsanim, Yuttitham Suteeka, Karn Pongsuwan, Prit Kusirisin, Nuttanun Wongsarikan, Kanda Fanhchaksai, Chantana Khamwan, Dararat Dankai, Vuddhidej Ophascharoensuk
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Vaccines
Subjects:
COVID-19
inactivated vaccine
replication-defective viral vectors vaccine
vaccine immunogenicity
hemodialysis
Online Access:https://www.mdpi.com/2076-393X/11/4/715

Internet

https://www.mdpi.com/2076-393X/11/4/715

Similar Items